We serve Chemical Name:2,4,5-Triiodoimidazole CAS:1746-25-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,4,5-Triiodoimidazole
CAS.NO:1746-25-4
Synonyms:1H-Imidazole, 2,4,5-triiodo-;2,4,5-Triiodo-1H-imidazole;MFCD00068812;2,4,5-Triiodoimidazole
Molecular Formula:C3HI3N2
Molecular Weight:445.767
HS Code:2933290090
Physical and Chemical Properties:
Melting point:188-190ºC
Boiling point:459.2±50.0 °C at 760 mmHg
Density:3.5±0.1 g/cm3
Index of Refraction:1.864
PSA:28.68000
Exact Mass:445.727356
LogP:2.78
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1H-Imidazole, 2,4,5-triiodo- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4,5-Triiodoimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Imidazole, 2,4,5-triiodo- Use and application,1H-Imidazole, 2,4,5-triiodo- technical grade,usp/ep/jp grade.
Related News: ICIG has agreed to offer employment to the unit��s approximately 120 employees upon closing, and plans to maintain operations at its primary location, a manufacturing facility in Liestal, Switzerland. 2,4,5-Triiodoimidazole manufacturer New Zealand on Sunday became the latest country to impose restrictions on travelers from mainland China, saying it would deny entry to visitors departing from or transiting through the mainland for two weeks starting on Monday. 2,4,5-Triiodoimidazole supplier Among 30,000 volunteers — all of them from either the United States or Mexico — vaccinated people were completely protected against severe and even moderate cases of illness. 2,4,5-Triiodoimidazole vendor Among 30,000 volunteers — all of them from either the United States or Mexico — vaccinated people were completely protected against severe and even moderate cases of illness. 2,4,5-Triiodoimidazole factory Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study.
